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Abstract
Objective To report the number of participants needed to recruit per
baby born to trial staff during AVERT, a large international trial on acute
stroke, and to describe trial management consequences.
Design Retrospective observational analysis.
Setting 56 acute stroke hospitals in eight countries.
Participants 1074 trial physiotherapists, nurses, and other clinicians.
Outcomemeasures Number of babies born during trial recruitment per
trial participant recruited.
ResultsWith 198 site recruitment years and 2104 patients recruited
during AVERT, 120 babies were born to trial staff. Births led to an
estimated 10% loss in time to achieve recruitment. Parental leave was
linked to six trial site closures. The number of participants needed to
recruit per baby born was 17.5 (95% confidence interval 14.7 to 21.0);
additional trial costs associated with each birth were estimated at 5736
Australian dollars on average.
Conclusion The staff absences registered in AVERT owing to parental
leave led to delayed trial recruitment and increased costs, and should
be considered by trial investigators when planning research and
estimating budgets. However, the celebration of new life became a
highlight of the annual AVERT collaborators’ meetings and helped
maintain a cohesive collaborative group.
Trial registration Australian New Zealand Clinical Trials Registry no
12606000185561.
Disclaimer Participation in a rehabilitation trial does not guarantee
successful reproductive activity.
Correspondence to: J Bernhardt Julie.Bernhardt@florey.edu.au
Data supplements on bmj.com (see http://www.bmj.com/content/351/bmj.h6432?tab=related#datasupp)
Web appendix 1: AVERT baby count graph
Web appendix 2: Summary of recruitment rate pre and post birth
Web appendix 3: Estimated additional costs due to AVERT team births
Web appendix 4: AVERT committees, advisors and coordinating centres
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Trial governance and good clinical practice dictates detailed
gathering of serious adverse events and SUSARs—that is,
suspected unexpected serious adverse reactions—in trials. In
the large international trial on acute stroke, AVERT (a very
early rehabilitation trial), we became aware early on of a
particular phenomenon of another SUSAR—special unexpected
staff absences registered, owing to babies born to trial clinical
staff.
Initially, these events were joyfully communicated to the
AVERT collaborators via congratulatory emails and birth notices
in the monthly AVERT investigator newsletters (featuring a
range of stork Clipart). Inquiries to the site lead investigator
followed, to determine recruitment plans of a new teammember.
However, as these baby related SUSARs accumulated,
management tracked these events in detail to assess their effect
on trial progress. In this retrospective analysis, we report the
frequency of births and the management team’s response to the
events; model the effect of babies born on recruitment, staff
training, and financial management; and discuss how baby
tracking influenced the morale of the study investigators.
Methods
Study design and trial staff
The design and primary results of AVERT, which tested the
hypothesis that early and frequent mobility training after a stroke
could reduce disability, have been published previously.1-3 This
pragmatic trial was fully embedded into the acute hospital
environment. Typically, sites were publicly funded hospitals.
Trial staff included hospital clinicians (physiotherapists and
nurses already employed at the site) who delivered the
intervention and other hospital staff (clinical or Stroke Research
Network employees in the United Kingdom) who recruited
patients or provided blinded follow-up of participants.
Management was undertaken at the central coordinating office
(known as AVERT Central). We provided onsite training at
study initiation, repeated as necessary for new trial staff. Annual
investigator meetings helped maintain intervention fidelity and
foster close communication between site teams and AVERT
Central.
Procedures and study data
During the initial (pilot) phase (2006-08), trial staff members
informally notified AVERTCentral with their birth news. From
2008, more formal methods of case ascertainment were used.
We asked trial staff to notify the central coordinating office of
any trial parental leave. Additionally, routine reminders to share
baby news were made via regular emails, telephone calls, site
visits, and monthly newsletters. An updated baby count graph
(web appendix 1) was regularly presented at investigators’
meetings, during which the effect on staff morale was
determined by a subjective “laughometer.” We maintained a
register of all trial staff, their qualifications, and duration of
their trial participation. Active months of recruitment for each
site and recruitment per month, the total number of staff working
on the trial, staff turnover, and the number of site visits required
for training new staff were recorded.
Outcomes
The primary outcome was the number of trial participants
needed to recruit per baby born to trial staff (NNRpB),
calculated as the ratio of the total number of patients recruited
in AVERT to the number of babies born to trial staff. The
secondary outcome was the costs of added recruitment years,
reported as total costs and mean costs per birth episode.
Analysis
Wegrouped countries into three regions: Australia/NewZealand,
Asia (Singapore, Malaysia), and the UK (England, Northern
Ireland, Scotland, andWales). Staff members who took parental
leave were included in this analysis. NNRpB measures were
reported as ratios with binomial 95% confidence intervals. We
compared differences in NNRpB between participating regions
using Fisher’s exact test.
To illustrate the effect of the SUSARs, we also present a case
study from one foundation site involved since trial
commencement. Costs were calculated retrospectively from
AVERT Central records, by use of estimated costs for closing
and opening new sites (such as site visits, administrative time,
and ethical considerations) and additional training time for new
staff (including travel costs). Total costs and cost per birth are
reported in 2015 Australian dollars ($A).
Patient involvement
A stroke survivor contributed to all stages of the development
and the conduct of the AVERT trial as a consumer representative
on the trial steering committee, the management committee and
on manuscript writing groups. The burden of trial intervention
was reported by each patient at the end of each therapy session,
however, overall trial burden to patients and family was not
evaluated. Biannual trial newsletters have been distributed to
patients throughout the trial and patients were invited to describe
their experience of stroke and the trial in this newsletter. The
trial results will be distributed to participants by hospital trial
staff on completion of the trial.
Results
For AVERT, we randomised 2104 participants from 56 sites
between 18 July 2006 and 16 October 2014, during a total of
198 recruitment years (calculated as the total time each site was
involved in the trial). Of 1074 trial staff registered, 926 were
women and 148 were men (man to woman ratio of 1:6.3). These
workers included 629 nurses, 284 physiotherapists, 50
occupational therapists, 38 assistant clinicians, three speech and
language therapists, one psychologist, and 69 physicians. The
median age was 28.0 (interquartile range 24.0-36.8) years.
We were notified of 29 babies born in the pilot phase. A further
91 babies (total n=120) were born to 97 site staff (table 1⇓).
Eleven additional babies born to AVERTCentral staff were not
included in the primary analysis, which focused on the effect
of birth on recruitment. The number of babies born per parent
ranged from one to three, and included four multiple births,
equating to 116 pregnancies delivered.
The NNRpB was 17.5 (95% confidence interval 14.7 to 21.0)
overall. There was a significant difference in NNRpB by region
(P=0.002), with Australia/New Zealand showing the lowest
value and Asia the highest. The hazard ratio of patients recruited
per baby born was 5.0 in Asia (95% confidence interval 1.6 to
15.4; P=0.005) and 1.8 in the UK (1.2 to 2.9; P=0.009),
compared with Australia/New Zealand. Figure 1⇓ shows patient
and baby accrual.
Twenty trial main investigators from 15 sites went on parental
leave during the course of the trial. We observed slowing of
recruitment during the staff transition phase in most instances.
In six instances, birth led to site closure when no alternative
local trial champion could be recruited (web appendix 2).
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However, 46 (47%) parents returned to the trial after parental
leave.
Case study
At one foundation site involved for the entire trial, a total of 15
babies were born to trial staff (four born to main investigators)
over eight recruitment years (fig 2⇓). Ten additional training
sessions were needed for replacement of staff. Three staff had
more than one baby, so only 10 sessions were needed. Each
training session lasted an average of 2.5 h (total 25 h).
Additional administrative management of staff changeover was
estimated at about 16 h per session (160 h in total). This extra
time was spent on appointments, travel, printing and supply of
required documents, administrative tracking, database access
setup, report writing and feedback to site, ethics notification,
and additional queries by site.
Costs
Births resulted in an estimated 232 months (19 years) of
recruitment loss out of our total of 198 recruitment years. Costs
arising from births were conservatively estimated at $A0.665m
or $A5736 (£2744; €3895; US$4124) per birth episode (web
appendix 3).
Staff morale
Each presentation of the baby count graph (web appendix 1) to
investigators resulted in loud chuckles.
Discussion
A surprisingly large number of babies were born to AVERT
staff during the trial, the unexpected consequences of which
included a high number of new recruits, more training, and
additional recruitment time and costs. Furthermore, we estimated
that site closures or paused recruitment due to parental leave of
a critical staff member lost 19 years of recruitment. Parental
leave represents a previously unreported source of trial burden
on hospital sites and trial coordinating teams. Our estimate of
17.5 NNRpB should assist investigators in planning similar
trials in the future.
We believe that AVERT staff were representative of public
hospital staff. In Australia, the average age of nurses and
physiotherapists is 39.9 years and 36.6 years, respectively, with
a ratio of 1 man to 7.6 women.4 5 In Scotland,6 44% of allied
health professionals (including physiotherapists) and 33% of
nurses are aged less than 40 years, with a ratio of 1 man to 6.7
women. The median age of AVERT staff was somewhat
younger. It is unclear whether stroke units attract younger,
largely female staff, or whether participation in AVERT was
attractive to this group. Older staff with additional
responsibilities appeared less inclined to take up a role in the
trial. Our results illustrate that planned research involving stroke
unit staff should consider the family plans of this group.
The trial challenges we experienced with parental leave reflect
the broader challenges in the community. The Australian
pregnancy and return to work national review described
employers reporting difficulties filling maternity leave positions
owing to their often short term nature.7 When external
recruitment is necessary, costs and delays increase.7 Clinical
care, as well as clinical research, can both be affected in these
circumstances.
AVERT, like many ambitious randomised controlled trials, took
longer than planned to complete recruitment; our unexpected
baby count added costs and delays, requiring grants from many
funding agencies around the world (see acknowledgments).
Although we wish to alert other researchers to these unexpected
costs, we have some additional reflections. Trial success requires
careful nurturing of many collaborators, with regular
collaborator meetings an essential ingredient of the esprit de
corps. Our baby graph became a positive part of the AVERT
experience, enjoyed at meetings as a celebration of life.
Strengths and limitations
Strengths of the study included its international reach and large
workforce. Results should be generalisable to other rehabilitation
studies. However, it is possible that full baby ascertainment was
not achieved. We did not systematically conduct exit
questionnaires when staff left the study. Impaired memory
associated with late pregnancy could have also reduced reporting
of baby related information to the trials team,8 which
underestimated the workforce fertility rate. Unmeasured factors
such as parental leave policy and maternal obesity 9 10 could
moderate the association between NNRpB and country. Finally,
because only two of our sites were in Asia, the regional
differences observed could have been due to chance.
Conclusions
The AVERT trial was associated with a large number of
unexpected babies born to trial staff. It is possible that the
challenges of trial participation resulted in some teammembers
deciding that having a child would be an easier option at this
stage of their lives. It is fair to say, however, that many returned
to their senses and resumed their AVERT roles, having realised
that research and patient care is perhaps more satisfying than
changing endless nappies.
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What is already known on this topic
Parental leave represents a previously unreported source of trial burden on hospital sites and trial coordinating teams
What this study adds
Ongoing recruitment and training of new staff is needed to cover parental leave among a young research workforce and the resulting
financial costs, which should be considered when planning research and estimating budgets
Celebrating the good stuff, including babies, in large trial collaborations is important, helping to maintain a cohesive collaborative group
Ethics approval: All hospitals participating in the study received ethics
approval.
Data sharing: No additional data available.
The lead author (the manuscript’s guarantor) affirms that the manuscript
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Table
Table 1| Patient recruitment, babies born to AVERT trial staff, and number of participants needed to recruit per baby born (NNRpB)
NNRpB (95% CI)No of babiesNo of patients recruited
All regions combined
17.5 (14.7 to 21.0)120*2104Total
By region
62.7 (24.8 to 229.4)4251Asia
15.0 (12.2 to 18.7)831243Australia/New Zealand





*11 additional babies born to staff at AVERT Central (the central coordinating trial site) were not included because the staff did not recruit patients.
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Figures
Fig 1 Accumulated recruitment of patients and babies born during AVERT
Fig 2 Case study from one selected trial site showing recruitment of patients, babies born to site investigators, and onsite
training delivered
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